US Edition
Avista Therapeutics and Forge Biologics Partner to Advance Gene Therapy for X-Linked Retinoschisis
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Avista Therapeutics and Forge Biologics Partner to Advance Gene Therapy for X-Linked Retinoschisis
Avista Therapeutics and Forge Biologics have announced a strategic partnership to accelerate the development and manufacturing of AVST-101, Avista’s lead gene therapy candidate for X-linked retinoschisis (XLRS). AVST-101 is a next-generation gene therapy engineered for efficient intravitreal delivery, low-dose efficacy, and broad retinal coverage, aiming to provide a safer and more accessible treatment option for patients. “Partnering with Avist…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
